A Rare Dog Nosebleed Condition That Responded to a Common Drug
Dog nosebleed issues can be alarming — and when they are caused by a rare condition affecting blood vessels in the nose, they can be especially hard to treat. A case report published in the journal Animals described two dogs with a rare condition called nasal alar arteriopathy (say: NAY-zul AY-lar ar-TEER-ee-OP-uh-thee), which simply means a disease of the tiny blood vessels in the outer part of the nose. Both dogs developed painful ulcers and bleeding around their nasal area. When treated with oclacitinib — a drug many pet owners know as Apoquel, commonly prescribed for itching and allergies — both dogs reached initial remission, meaning their symptoms went away or greatly improved.
This is small-scale, early-stage evidence. Only two dogs were involved, so it cannot be called a proven treatment. But for a condition with very few known treatment options, this report adds useful information to what vets can consider.
Why This Condition Is So Hard to Manage
Nasal alar arteriopathy is a rare disease that affects the tiny blood vessels in the soft tissue on either side of a dog’s nose — the outer rim of the nostrils and surrounding skin folds. When these vessels malfunction, the skin in that area can break down into open sores (ulcers) that bleed and resist healing.
Because the condition is so uncommon, there is very little published research on how to treat it. Vets diagnosing it need to take a biopsy — a small tissue sample from the affected area examined under a microscope — to confirm what is happening. Without that step, it is easy to confuse this condition with other skin or nasal problems.
The limited treatment options are frustrating for both vets and dog owners. That is what makes even a small case report like this one worth noting.
What the Study Looked At
The report covers two client-owned dogs who both had confirmed nasal alar arteriopathy, with persistent ulcers and bleeding at the nose. Their vets tried oclacitinib as a treatment option.
Oclacitinib works by blocking certain chemical signals inside immune cells — signals that drive inflammation and itching. Think of it like turning down a dial on the immune system’s alarm response. It is widely used in dogs for allergic skin disease, and vets already have a solid understanding of how it behaves.
Key details from the report:
- Number of dogs: 2
- Condition: Nasal alar arteriopathy, confirmed by biopsy
- Treatment used: Oclacitinib (Apoquel) given on its own, without other medications
- Result: Both dogs achieved initial clinical remission — their symptoms improved to the point of going away or being well controlled
What the Findings Tell Us
The main finding is that oclacitinib helped both dogs reach initial remission from this rare condition. This points to the immune system playing a role in nasal alar arteriopathy. Oclacitinib’s ability to calm immune-driven inflammation may explain why it worked.
However, the report does not tell us:
- How long the remission lasted — whether it was short-lived or sustained
- What dose or treatment length was used — no standard protocol is established
- Whether oclacitinib is safe long-term for this specific condition — the evidence is too limited to know
This is very early information. Two cases are enough to suggest oclacitinib is worth exploring further, but not enough to recommend it as a standard treatment.
What This Means for You and Your Dog
If Your Dog Has Persistent Nose Sores or Bleeding
Ulcers or repeated bleeding near a dog’s nose and nostrils can have many causes — from minor skin infections to more serious underlying conditions. If your dog has sores that keep coming back around the nose area, that is a reason to get a veterinary evaluation. Do not try to manage it at home without knowing the cause first.
Diagnosis Comes First
The researchers stress that nasal alar arteriopathy requires a biopsy to diagnose accurately. This matters because other conditions can look very similar on the surface. Treating the wrong diagnosis will not help and could cause delays in getting the right care.
Talk to Your Vet About Options
If your dog is diagnosed with this condition, this case report gives your vet something to consider. Oclacitinib (Apoquel) is already a familiar drug in veterinary medicine. Asking your vet whether it might be appropriate for your dog’s situation is a reasonable conversation.
That said, do not push for oclacitinib based on this report alone. Treatment decisions depend on your dog’s full health picture and your vet’s clinical judgment.
Study Limitations
This report covers only two dogs — an extremely small number. Two cases cannot establish:
- That oclacitinib works reliably for this condition across many dogs
- The right dose or length of treatment
- Long-term safety for this specific use
- Whether remission was truly due to oclacitinib or other factors
The authors acknowledge these limits directly and call for larger studies. For now, the report expands a very thin body of knowledge about a rare disease — and that is its main value.
The Bottom Line
Two dogs with a rare nose-bleeding condition called nasal alar arteriopathy both reached initial remission after being treated with oclacitinib, according to a new case report in Animals. This is promising early information for a disease with few known treatment options. With only two cases studied, however, it is far too soon to call this a proven standard treatment.
If your dog has recurring nose ulcers or unexplained bleeding near the nostrils, see your vet. A proper diagnosis — including a biopsy — is the essential first step. Ask your vet whether oclacitinib might be worth exploring based on your dog’s specific situation and diagnosis.
This article summarizes peer-reviewed research for educational purposes. Always consult with your veterinarian for personalized advice about your pet’s health and behavior.